Paperpal Prime Logo

Therapeutic Advances in Neurological Disorders : Impact Factor & More

eISSN: 1756-2864pISSN: 1756-2856
JournalOpen Access

Key Metrics

CiteScore
9.4
Impact Factor
5 - 10
SJR
Q1Neurology
SNIP
1.87
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Therapeutic Advances in Neurological Disorders

Therapeutic Advances in Neurological Disorders Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
  • Scopus Scopus
  • DOAJ DOAJ
  • SJR SJR
Overview
Publisher SAGE PUBLICATIONS LTD
Language English
Frequency Continuous publication
Article Processing ChargesUSD 2300
Publication Time15
Editorial Review ProcessAnonymous peer review
General Details
LanguageEnglish
FrequencyContinuous publication
Publication Start Year2008
Publisher URLVisit website
Website URLVisit website
Publication Details
PlagiarismVisit website
Publication Time 15
Waiver PolicyVisit website
Editorial Review Detail
Editorial TeamVisit website
Review ProcessAnonymous peer review
Review UrlVisit website
Information for authors
Author instructionsVisit website
Copyright DetailsVisit website
Deposit PolicySherpa/Romeo
License typeCC BY, CC BY-NC
OA statementVisit website
View less

Planning to publish in Therapeutic Advances in Neurological Disorders ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Therapeutic Advances in Neurological Disorders

A multicentre study on predictors of relapses in AQP4-IgG NMOSD: Do titres matter?
  • 1 Oct 2026
  • Therapeutic Advances in Neurological Disorders
Relapsing anti-mGluR1 encephalitis with atypical temporal lobe manifestations – response to rituximab and recurrence with B-cell reconstitution
  • 1 Oct 2026
  • Therapeutic Advances in Neurological Disorders
Non-ischemic cerebral enhancing (NICE) lesions after extracranial carotid stenting: A case report
  • 1 Oct 2026
  • Therapeutic Advances in Neurological Disorders
Contraindications to endovascular treatment in acute ischemic stroke: Where evidence ends and structured reasoning begins
  • 1 Oct 2026
  • Therapeutic Advances in Neurological Disorders
Strategic positioning and long-term management of immune reconstitution therapies in multiple sclerosis: An expert consensus
  • 1 Oct 2026
  • Therapeutic Advances in Neurological Disorders
Alzheimer’s disease and olfactory dysfunction: the role of TNF-α and mechanisms involving ferritin and P-tau199 from an exploratory cross-sectional study
  • 1 Oct 2026
  • Therapeutic Advances in Neurological Disorders
A multicentre study on predictors of relapses in AQP4-IgG NMOSD: Do titres matter?
  • 1 Oct 2026
  • Therapeutic Advances in Neurological Disorders
Relapsing anti-mGluR1 encephalitis with atypical temporal lobe manifestations – response to rituximab and recurrence with B-cell reconstitution
  • 1 Oct 2026
  • Therapeutic Advances in Neurological Disorders
Non-ischemic cerebral enhancing (NICE) lesions after extracranial carotid stenting: A case report
  • 1 Oct 2026
  • Therapeutic Advances in Neurological Disorders
Contraindications to endovascular treatment in acute ischemic stroke: Where evidence ends and structured reasoning begins
  • 1 Oct 2026
  • Therapeutic Advances in Neurological Disorders
Strategic positioning and long-term management of immune reconstitution therapies in multiple sclerosis: An expert consensus
  • 1 Oct 2026
  • Therapeutic Advances in Neurological Disorders
Alzheimer’s disease and olfactory dysfunction: the role of TNF-α and mechanisms involving ferritin and P-tau199 from an exploratory cross-sectional study
  • 1 Oct 2026
  • Therapeutic Advances in Neurological Disorders

FAQs on Therapeutic Advances in Neurological Disorders